Financials

v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Current Assets    
Cash $ 126,362 $ 245,026
Accounts receivable 171,043 157,069
Other receivables 99,237 86,888
Inventory 306,437 294,714
Prepaid expenses 140,040 204,532
Short-term receivable 150,000
Total Current Assets 843,119 1,138,229
Property and Equipment, net of accumulated depreciation 80,144 87,173
Deposits 2,751 2,751
Total Assets 926,014 1,228,153
Current Liabilities    
Interest payable 70,996 69,222
Accounts payable 510,770 196,171
Accounts payable to related parties 13,171 12,319
Accrued liabilities 90,000 64,000
Notes payable, current portion 110,217 132,294
Short-term note payable, net of debt discount 176,919
Convertible debt 100,000
Unearned revenue 1,048
Total Current Liabilities 1,072,073 475,054
Long-Term Liabilities    
Notes payable, net of current portion 22,434 38,990
Deferred rent 393 688
Total Long-Term Liabilities 22,827 39,678
Total Liabilities 1,094,900 514,732
Stockholders' (Deficit) Equity    
Preferred stock - $.001 par value: 500,000 shares authorized, no shares issued and outstanding at March 31, 2018 (unaudited), 12,740 shares issued and outstanding at December 31, 2017 13
Common stock - $.001 par value: 49,500,000 shares authorized, 23,207,013 and 21,163,013 shares issued and outstanding at March 31, 2018 (unaudited) and December 31, 2017, respectively 23,207 21,163
Additional paid-in capital 33,879,096 33,509,648
Accumulated deficit (34,071,189) (32,817,403)
Total Stockholders' (Deficit) Equity (168,886) 713,421
Total Liabilities and Stockholders' (Deficit) Equity $ 926,014 $ 1,228,153

Source

v3.8.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]    
Revenues $ 144,182
Less: Discounts Allowed (993)
Cost of Goods Sold (98,095)
Gross Profit 45,094
Operating Expenses    
General and administrative 896,422 1,423,229
Sales and marketing 250,430 82,137
Research and development 139,124 335,440
Depreciation 7,029 6,221
Total Operating Expenses 1,293,005 1,847,027
Operating Loss (1,247,911) (1,847,027)
Other Expenses    
Foreign currency transaction loss 393
Interest expense 5,482 390,798
Total Other Expenses 5,875 390,798
Total Loss from Continuing Operations (1,253,786) (2,237,825)
Discontinued Operations    
Loss from discontinued operations 1,163
Total Loss from Discontinued Operations (1,163)
Net Loss $ (1,253,786) $ (2,238,988)
Loss per share – Basic and Diluted:    
Continuing Operations $ (0.06) $ (0.14)
Discontinued Operations
Net Loss per share $ (0.06) $ (0.14)
Weighted average outstanding shares used to compute basic and diluted net loss per share 21,473,657 16,271,075

Source

v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash Flows from Operating Activities    
Net loss $ (1,253,786) $ (2,238,988)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 7,029 6,221
Amortization of debt discount 2,565 31,772
Debt conversion expense 356,400
Stock based compensation 51,333 605,833
Straight-line rent adjustment (295)
Changes in operating assets and liabilities, net of effects of disposition:    
Accounts receivable (13,974)
Other receivables (12,349)
Prepaid expenses 64,492 203,150
Inventory (11,723)
Accounts payable 314,599 (5,025)
Accounts payable to related parties 852
Interest payable 1,774
Unearned revenue (1,048)
Accrued liabilities 26,000 (414,800)
Net Cash Used in Operating Activities (824,532) (1,455,437)
Cash Flows from Investing Activities    
Payment received from Streamline note receivable 150,000
Expenditures for property and equipment (3,080)
Net Cash Provided by (Used in) Investing Activities 150,000 (3,080)
Cash Flows from Financing Activities    
Principal payments under note payable obligations (38,633) (59,686)
Proceeds from issuance of common stock, net of offering costs 231,877 1,923,248
Proceeds from issuance of warrants, net of offering costs 62,623 694,812
Proceeds from issuance of convertible debt 100,000
Proceeds from issuance of short term loan 200,000
Net Cash Provided by Financing Activities 555,868 2,558,374
Net (Decrease)/Increase in Cash (118,664) 1,099,857
Cash - Beginning of period 245,026 892,814
Cash - End of period 126,362 1,992,671
Supplementary Cash Flow Information    
Cash paid for interest 1,931 3,037
Non-cash investing and financing activities    
Financing agreement for insurance policy 37,336 44,701
Conversion of short-term loan to common stock 126,720
Issuance of common stock for consideration of cancellation of warrants 208,000
Issuance of warrants for conversion of notes 305,201
Common stock issued for board fees 240,000
Issuance of common stock for preferred stock conversion 1,274 411
Issuance of warrants for promissory note $ 25,646

Source

Disclaimer

Medovex Corp. maintains this website as a service to the financial and internet communities. The site is intended to provide general information about the Company. It is not designed to be a source for making investment decisions. Medovex will make every reasonable effort to include accurate and current information on this website.

Except for the historical information contained herein, the information on the site may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. More complete information is contained in the company’s SEC filings.

Neither Medovex Corp nor any party involved in creating, producing or delivering this site shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of the user’s access, use, or liability to use the Company’s website, or any errors or omissions in the content of the Medovex Corp website.

Terms of Use
General

Medovex Corp. (“the Company”) has made a reasonable effort to provide accurate and current information on this website.

It is important to note that nothing on our website constitutes or should be construed as investment advice. Date and information presented is not furnished in connection with any sale, offer of sale, solicitation or an offer to buy a security.

Solicited Policy

Neither Medovex nor any of its employees accept or consider unsolicited ideas regarding marketing, technologies or product names. The goal is to avoid any potential misunderstandings when Medovex’s products or marketing strategies might appear similar to ideas submitted to the Company.

No Offer or Advice

This website does not constitute an offer to sell or a solicitation of an offer to buy any security referenced on this website. Medovex’s management never represents that a security, product or service discussed here, are suitable for any particular investor. We do not guarantee the accuracy, completeness or timeliness. We strongly advise that all individuals be aware of the risks involved in every business and stock. You can help protect yourself by being an educated investor by closely examining Company documents filed with the Securities and Exchange Commission (SEC) as well as all other documents that have been published.

Limitation of Liability – SEC Rule 606

Use of this website is at the viewer’s own risk. Its content including but not limited to: any graphics, links or other terms are provided on an “as is” basis without warranties or representations of any kind. The Company expressly disclaims any liability for any errors or omissions in the content included in this website. All changes (should and when they may occur) are effective immediately upon posting to this website.

Archived and Forward Information

Any reports filed with the SEC may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks, some of which may be outside the Company’s control and may include economic, political and market fluctuations. Medovex undertakes no obligation to update or revise publicly any forward looking statement whether as a result of new information, future events or otherwise.

The Company strongly recommends readers carefully review all other documents and periodic reports filed by the Company with the SEC.

Medovex cannot and does not guarantee or warrant that files available for downloading (if any) through this site will be free of infection by software viruses or other harmful computer code, files or programs.